Dublin, May 21, 2021 (GLOBE NEWSWIRE) -- The "Oncology/Cancer Drugs Market by Drug Class Type and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
The global oncology drugs market was valued at $128,352 million in 2019, and is projected to reach $222,380 million by 2027, registering a CAGR of 7.4%.
Cancer is the uncontrolled growth of abnormal cells in the body. Cancer develops when the body's normal control mechanism stops working. Old cells do not die and instead grow out of control, forming new, abnormal cells. The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types. Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.
However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.
The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA
The study provides an in-depth analysis of the global oncology/cancer drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
The report provides a quantitative analysis for the period of 2019-2027 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market by components helps to understand the various types of instruments used across geographies.
Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these regions.
Key market players have been profiled in the report and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.
Extensive analysis of the market is conducted by closely following key product positioning, and monitoring the top contenders within the market framework.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.3. Top player positioning, 2019
3.4. Porter's five forces analysis
3.5. Clinical trials
3.6. Market dynamics
188.8.131.52. Rise in incidence of cancer across the globe
184.108.40.206. Surge in global geriatric population
220.127.116.11. Increase in government expenditure on healthcare
18.104.22.168. Adverse effects associated with the use cancer drugs
22.214.171.124. High growth potential in untapped emerging economies
126.96.36.199. Increase in number of pipeline drugs
3.6.4. Impact analysis
3.7. COVID-19 impact analysis on oncology/ cancer drugs market
CHAPTER 4: ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE
CHAPTER 5: ONCOLOGY/ONCOLOGY/CANCER DRUGS MARKET, BY INDICATIION
CHAPTER 6: ONCOLOGY/CANCER DRUGS MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES
7.1. ABBVIE INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AMGEN INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. ASTELLAS PHARMA INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. ASTRAZENECA PLC.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. BRISTOL-MYERS SQUIBB COMPANY
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. F. HOFFMANN-LA ROCHE LTD.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance.
7.6.6. Key strategic moves and developments
7.7. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. MERCK & CO., INC.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. NOVARTIS INTERNATIONAL AG (SANDOZ)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. PFIZER INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
For more information about this report visit https://www.researchandmarkets.com/r/a0vdo8
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900